Redeye has a favourable view of the topline results presented by Cantargia at ASCO 2022, which we di...
With fresh funding in place and the FDA’s response to a pre-IND application, AlzeCure is evolving in...
Eastnine redovisar tillväxt i hyresintäkterna under kvartalet och genomför en större nedskrivning i ...
Sales worse than feared, but isolated to Q1 conditions Clinical and commercial progress bodes well f...
Gullberg & Jansson redovisar ett stabilt första kvartal och växer försäljningen med mer än 50 procen...
Redeye feels disappointed following FDA requesting complimentary information ahead of accepting the ...
Component issues holding back near-term sales GARO well-positioned to accelerate growth in H2 Mainta...
Upplevelsebolaget Bodyflight redovisade ett starkt första kvartal för 2022 som bekräftade vår invest...
Thinc Jetty-koncernen visade 34 procent organisk intäktstillväxt i kv1 2022.
Redeye states that the Q1 report was below our expectations due to a one-time payment and slightly l...
Watch the company presentation ahead of Redeye Growth Day 2022.
Produktmixen fortsätter påverka marginalen Nettoomsättningen i Q1'22 uppgick till EUR 40m (EUR 28m i...
Euroafrica Digital Ventures AB publicerade den 25 maj 2022 bolagets delårsrapport för första kvartal...
New initiatives to grow subscription sales in the pipeline Seasonality changes and adding new revenu...
EPTI published, May 24th, its interim report for the first quarter of 2022.
EPTI publicerade den 24 maj bolagets delårsrapport för första kvartalet 2022.
1.1 million infants die annually, where 80% suffer from Respiratory Distress Syndrome (RDS).
Redeye sees a weaker report than expected due to supply chain delays and covid issues that made orde...
Manoush Masarrat, CEO at Inhalation Sciences, held a strategy update at Redeye on May 24.
Redeye believes the updated strategy and redirected focus makes a lot of sense.
